20
DSM-IV-TR 300.7

B O D ( Y)

Embed Size (px)

Citation preview

Page 1: B  O  D ( Y)

DSM-IV-TR 300.7

Page 2: B  O  D ( Y)

The defect is either imagined or if a physical anomaly is present individuals exhibit excessive concern

Preoccupation must cause significant distress or impairment in social, occupational, or other areas of functioning

The preoccupation is not better accounted for by other mental D/O (e.g. body shape in Anorexia Nervosa

Page 3: B  O  D ( Y)

Thinning hairAcne

WrinklesScarsVascular Markings

Pale or Red complexion

SwellingFacial disproportion

Shape or size of:Nose

EyesEyebrowsEars

MouthLipsTeeth

JawCheeks/ChinSize of muscles

Page 4: B  O  D ( Y)

The genitals, buttocks, abdomen, arms, hands, feet, hips, shoulders, or overall body size and shape.

Preoccupation may focus on several body parts.

Individuals will avoid describing defects because of embarrassment. They will only refer to their general ugliness.

Page 5: B  O  D ( Y)

http://www.youtube.com/watch?v=iAuc2xAM7-8

Page 6: B  O  D ( Y)

PREOCCUPATION, MAY BE NO EFFORT TO RESIST PREOCCUPATION, MAY BE

AVOIDING SCHOOL, WORK, FAMILY, & ACTIVITIES

Page 7: B  O  D ( Y)

CO-MORBID WITH AXIS 1 DX

OBSESSIVE COMPULSIVE D/O, SOCIAL PHOBIA, ANOREXIA NERVOSA, & SUBSTANCE ABUSE

Page 8: B  O  D ( Y)

MOST BDD CLIENTS HAVE CLUSTER C PERSONALITY D/O: AVOIDANT, PARANOID, OR OBSESSIVE COMPULSIVE PERSONALITY.

Page 9: B  O  D ( Y)

BDD MAY BEGIN IN CHILDHOOD, BUT USUALLY OCCURS IN ADOLESCENCE AND YOUNG ADULTS.

Average age of onset is 16 – 17 years although irmay be seen in older adults who are concerned with aging.

Affects 1-2% of the population

Affects men and women almost equally

No association between BDD and race

BDD is a chronic lifelong condition.

Page 10: B  O  D ( Y)
Page 11: B  O  D ( Y)

CULTURES WITH HIGH EMPHASIS ON BEAUTY AND APPEARANCE

PEOPLE FROM A HIGHER SOCIOECONOMIC STATUS OR HAVE STRICT CULTURAL STANDARDS MAY EXPERIENCE BDD MORE OFTEN

THEY MAY HAVE EXPERIENCED A TRAUMATIC EVENT OR CONFLICT DURING CHILDHOOD.

LOW SELF-ESTEEM HAVE PARENTS OR PEERS WHO ARE CRITICAL

OF THEIR APPEARANCE.

Page 12: B  O  D ( Y)

AS WITH OTHER SOMATAFORM DISORDERS BDD MAY ALSO BE CAUSED BY THE NEUROTRANSMITTERS IN THE BRAIN.

THERE MAY ALSO BE A GENETIC COMPONENT TO BDD.

Page 13: B  O  D ( Y)

Clients may come in for other problems i.e. relationship, anxiety, depression, or substance abuse.

It is important to get a thorough history, especially medical because they change physicians often.

Questions to ask: Do you avoid social

settings because of body concerns?

Do you feel you any problems in your physical appearance?

Does this cause any distress at work or social situations?

Does this prevent you from developing any sexual relationships?

Page 14: B  O  D ( Y)

Body Dysmorphic Exam Self Report:

This is a semi-structured interview designed to assess for obsessions, negative appearance concerns, self consciousness, embarrassment, camouflaging of body, or body adjusting.

Multidimensional Body-Self Relations Questionnaire:

Assess satisfaction of appearance and preoccupation with perceived defects.

Page 15: B  O  D ( Y)

Combination Therapy for treating BDD which includes:

Cognitive Therapy: This identifies negative beliefs, behavior, and thinking errors and replaces them with healthy coping strategies. These strategies include: challenging the clients negative cognitions, restructuring of learned behavior (skin picking or body checking), and challenging client to expose body part in a social setting.

Page 16: B  O  D ( Y)

Medication to help with the obsessive thoughts, depression, and anxiety.

It is important to help the client learn self care, follow the direction of their prescribed meds.

Helping them break the cycle and learning to focus on something else other than the anxiety about the body part.

Continue therapy, involve supportive family members, and continue to talk about it with someone.

Page 17: B  O  D ( Y)

Selective Serotonin Reuptake Inhibitors (SSRI’s) These Include:

Luvox

Zoloft

Celexa

Paxil

As per the American Psychiatric Association, medication should be re-evaluated 3-4 times per year.

Page 18: B  O  D ( Y)

APPROXIMATELY 53% OF THOSE WITH BDD EXPERIENCE A RELAPSE OF SYMPTOMS WHEN THEY DISCONTINUE MEDICATION.

BDD IS A CHRONIC LIFETIME ILLNESS CONTINUING THEIR MEDICATION MANAGEMENT AND THERAPY IS IMPORTANT TO DECREASE THE LIKLIHOOD OF RELAPSE.

Page 19: B  O  D ( Y)

PEOPLE WITH BDD FIND IT DIFFICULT TO MEET NEW PEOPLE AND MAKE FRIENDS.

UNTREATED BDD MAY LEAD TO DEPRESSION, SOCIAL ISOLATION, AND POSSIBLE SUICIDE.

HAVING SURGICAL PROCEDURES MAY WORSEN A PERSON WITH BDD PERCEPTIONS OF THE PERCEIVED FLAW – CAUSING ANGER AND LITIGIOS ACTION.

Page 20: B  O  D ( Y)

PROGNOSIS IS GOOD FOR CLIENTS WHO ARE DIAGNOSED, TREATED AND WHO STAY ON THEIR MEDICATION.

PROGNOSIS